Andrea Nicolás applies her scientific background and her knowledge of corporate law in advising clients in the areas of pharmaceuticals, biotechnology and health care at all stages of corporate development. 

Bio

Dr. Nicolás represents investment banks and issuers in a variety of public and private finance transactions in the U.S. and internationally. Her experience includes initial public offerings and other equity offerings as well as high-yield and investment grade debt offers and restructuring transactions such as exchange offers. Dr. Nicolás advises clients in a number of areas, including disclosure issues, corporate governance, compliance with securities laws and general corporate matters. She was named as a Rising Star in IFLR1000 2017, as one of The American Lawyer’s 2015 Dealmakers of the Year for advising NextEra Energy Inc. on its $467 million yieldco IPO, and as one of Latinvex’s Top 100 Female Lawyers in Latin America (2016-21).

Significant health care representations include:

  • Gain Therapeutics, Inc. in its IPO;
  • Nano-X Imaging Ltd. in its IPO and a follow-on offering of its ordinary shares;
  • BeiGene Ltd. in its IPO on the Hong Kong Exchange and global offering of its ordinary shares;
  • BeyondSpring Inc. in its IPO and multiple follow-on offerings;
  • Foamix Pharmaceuticals Ltd. (now Vyne Therapeutics, Inc.) in its IPO, multiple follow-on offerings and merger with Menlo Therapeuticals, Inc.;
  • Highbridge Capital Management in a debt-for-debt exchange offer by Protalix BioTherapeutic, Inc.;
  • Macrocure Ltd. in its IPO;
  • Omrix Biopharmaceutical, Inc. in its IPO and a follow-on offering of its common stock;
  • Patheon N.V. in its IPO;
  • Regeneron Pharmaceuticals, Inc. in multiple offerings of its common stock and convertible notes;
  • Barclays and Jefferies in connection with the IPO of Rewalk Robotics Ltd.; and
  • J.P. Morgan and Citigroup in connection with the IPO of Prosensa Holding B.V.

Other significant representations include:

  • NextEra Energy Partners, L.P. in its $467 million IPO, for which The American Lawyer named Dr. Nicolás a “Deal Maker of the Year”;
  • Party City, Inc. in its out-of-court debt restructuring, including a debt-for-debt and equity exchange offer and issuance of new secured debt by Anagram, a wholly owned subsidiary;
  • 8point3 Energy Partners LP, a joint venture growth-oriented limited partnership formed by First Solar and SunPower to own, operate and acquire solar energy generation projects, in its IPO;
  • Talen Energy Supply, LLC, an energy and power generation company, in multiple private placements of investment-grade debt and related tender offers; and
  • Shelf Drilling International Holdings, Ltd., in its formation financing, debt-for-debt exchange offers, an equity private placement and Norwegian OTC listing and multiple high-yield debt offerings.

Credentials

Education

  • J.D., Columbia University School of Law, 1998 (Harlan Fiske Stone Scholar)
  • Ph.D., Molecular Microbiology, Columbia University Graduate School of Arts & Sciences, 1995
  • B.S., Microbiology, State University of Maryland at College Park, 1989

Admissions

  • New York
  • U.S. Patent and Trademark Office

Andrea L. Nicolás